<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744390</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-IDEAL Study</org_study_id>
    <nct_id>NCT03744390</nct_id>
  </id_info>
  <brief_title>IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome</brief_title>
  <official_title>A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      patients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with&#xD;
      AG221 (IDH2 inhibitor)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myelodysplastic syndrome (MDS) are clonal hematopoietic stem cell disorders characterized by&#xD;
      ineffective hematopoiesis leading to blood cytopenia, especially anemia, and often evolving&#xD;
      to Acute myeloblastic Leukemia (AML). Main prognostic factors of MDS, for progression to AML&#xD;
      and survival, include the number and importance of cytopenias, percent marrow blasts and bone&#xD;
      marrow cytogenetic abnormalities. These factors are combined in an International Prognostic&#xD;
      Scoring System (IPSS) that distinguishes 4 subgroups with significantly different risk of&#xD;
      progression to AML and survival (low, intermediate 1 (int 1), intermediate 2 (int 2), high).&#xD;
      Low and int 1 subgroups are often grouped together as &quot;favorable &quot; or low risk MDS, and int 2&#xD;
      and high subgroups are &quot; unfavorable &quot; or high risk MDS.&#xD;
&#xD;
      On the other hand, only 50 to 60% of the patients respond to Azacitidine, and most responders&#xD;
      relapse within 12 to 15 months resulting in a median survival of only about 6 months in these&#xD;
      patients,. As a result there is a need for new therapies in patients who fail to respond to&#xD;
      azacitidine or decitabine and for whom there is currently no establish treatment.&#xD;
&#xD;
      Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes that convert&#xD;
      isocitrate to α-ketoglutarate. IDH1/2 mutations define distinct subsets of cancers, including&#xD;
      low-grade gliomas and secondary glioblastomas, chondrosarcomas, intrahepatic chol-, and&#xD;
      hematologic angiosarcomas c malignancies. Somatic point mutations in IDH1/2 confer a&#xD;
      gain-of-function in cancer cells, resulting in the accumulation and secretion in vast excess&#xD;
      of an antimetabolite, the D-2-hydroxyglutarate (D-2HG). Overproduction of D-2HG interferes&#xD;
      with cellular metabolism and epigenetic regulation, contributing to oncogenesis. Indeed, high&#xD;
      levels of D-2HG inhibit alpha-ketoglutarate-dependent dioxygenases, including histone and DNA&#xD;
      demethylases, leading to histone and DNA hypermethylation and finally a block in cell&#xD;
      differentiation.&#xD;
&#xD;
      preclinical studies have demonstrated that inhibition of IDH1/2-mutant enzymes decreases&#xD;
      intracellular D-2-hydroxyglutarate (D-2HG) levels, reverses epigenetic dysregulation, and&#xD;
      releases the differentiation block.&#xD;
&#xD;
      AG-221, a selective inhibitor of the IDH2 mutant enzyme Overall, in myeloid malignancies,&#xD;
      AG221 have been mainly used in generally heavily pretreated AML, with about 40% of responses&#xD;
      in patients with the respective IDH 1 and IDH2 mutations, and a median response duration&#xD;
      exceeding 1 year when CR or PR was achieved.&#xD;
&#xD;
      Based on these results, the investigators hypothesize that the IDH2 inhibitor (AG 221) may be&#xD;
      an effective therapeutic option in patient with IDH2 mutation-positive myelodysplastic&#xD;
      syndrome This is an open-label, single-arm multicenter, phase II study&#xD;
&#xD;
      The efficacy of AG 221 will be studied in 3 different groups of MDS patients with IDH-1&#xD;
      mutation:&#xD;
&#xD;
        -  Cohort A:Higher risk MDS (IPSS int-2, high) without response (CR,PR,stable disease with&#xD;
           HI) after at least 6 cycles of azacitidine or relapse after a response but without overt&#xD;
           progression (defined by at least doubling of marrow blasts, compared to pre azacitidine&#xD;
           bone marrow, or by AML progression beyond 30% blasts)&#xD;
&#xD;
        -  Cohort B:Untreated higher risk MDS (IPSS int-2, high) without life threatening&#xD;
           cytopenias (ie red blood cell (ANC) &lt; 500/mm3 or any recent severe infection and/or&#xD;
           platelets below 30,000/mm3 and any bleeding symptom). Azacitidine will be added after 3&#xD;
           cycles of AG-221 in the absence of response&#xD;
&#xD;
        -  Cohort C: Lower risk MDS with anemia resistant to erythropoietic stimulating agents&#xD;
           (primary or secondary resistance)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2019</start_date>
  <completion_date type="Anticipated">February 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall hematological response</measure>
    <time_frame>6 months</time_frame>
    <description>Overall hematological response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration Response</measure>
    <time_frame>3 years</time_frame>
    <description>Duration Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression IPSS</measure>
    <time_frame>3 years</time_frame>
    <description>Progression IPSS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Leukemia Acute Myeloid</condition>
  <arm_group>
    <arm_group_label>AG-221</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects enrolled will receive continuous 28-day cycles of AG-221 - 100 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AG-221</intervention_name>
    <description>Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.</description>
    <arm_group_label>AG-221</arm_group_label>
    <other_name>Enasidenib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
        Patients must meet all of the following criteria to participate in the study:&#xD;
&#xD;
          1. Myelodysplastic syndrome according to World Health Organization (WHO) classification&#xD;
             including non-proliferative AML up to 29% of Bone marrow (BM) blast&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Belonging to one of the following categories:&#xD;
&#xD;
               1. higher risk MDS (IPSS int-2, high) without response to azacitidine (Complete&#xD;
                  response (CR),Partial Response (PR), stable disease with HI) after at least 6&#xD;
                  cycles , or relapsing after a response but without overt progression (defined by&#xD;
                  at least doubling of marrow blasts, compared to pre azacitidine bone marrow, or&#xD;
                  AML progression beyond 30% blasts)&#xD;
&#xD;
               2. Untreated higher risk MDS (IPSS int-2, high) without life threatening cytopenia&#xD;
                  including absolute neutrophil count (ANC) &lt;500/mm3 or any recent severe&#xD;
                  infections and/or platelets below 30,000/mm3 and any bleeding symptom&#xD;
&#xD;
               3. Lower risk MDS with resistance or loss of response to a previous treatment with&#xD;
                  epoetin alpha/ beta (≥60000 U/w) or Darbopoetin (≥250 ug/w) given for at least 12&#xD;
                  weeks and red blood cell (RBC) transfusion requirement at least 2 U/8 weeks in&#xD;
                  the previous 16 weeks.&#xD;
&#xD;
          4. Presence of IDH2 mutation in either blood or marrow prior to start of therapy&#xD;
&#xD;
          5. Normal renal function, defined by creatinine less than 1.5 times the upper limit of&#xD;
             normal, creatinine clearance (Modification of diet in renal disease) (MDRD) ≥ 50&#xD;
             mL/min.&#xD;
&#xD;
          6. Normal liver function, defined by total bilirubin and transaminases less than 1.5&#xD;
             times the upper limit of normal.&#xD;
&#xD;
          7. Adequate cardiac ejection fraction (&gt;40%)&#xD;
&#xD;
          8. Patient is not known to be refractory to platelet transfusions.Written informed&#xD;
             consent.&#xD;
&#xD;
          9. Patient must understand and voluntarily sign consent form.&#xD;
&#xD;
         10. Patient must be able to adhere to the visit schedule as outlined in the study and&#xD;
             follow protocol requirements.&#xD;
&#xD;
         11. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 at the time of&#xD;
             screening.&#xD;
&#xD;
         12. Female subjects of child-bearing potential must agree to undergo medically supervised&#xD;
             pregnancy test prior to starting study drug. The first pregnancy test will be&#xD;
             performed at screening (within 7 days prior to first study drug administration), and&#xD;
             on the day of the first study drug administration and confirmed negative prior to&#xD;
             dosing and Day 1 before dosing all subsequent cycles.&#xD;
&#xD;
         13. Female subjects with reproductive potential must have a negative serum pregnancy test&#xD;
             within 7 days prior to the start of therapy. Subjects with reproductive potential are&#xD;
             defined as sexually mature women who have not undergone a hysterectomy, bilateral&#xD;
             oophorectomy or tubal occlusion or who have not been naturally postmenopausal (i.e.,&#xD;
             who have not menstruated at all) for at least 24 consecutive months (i.e., has had&#xD;
             menses at any time in the preceding 24 consecutive months). Females of reproductive&#xD;
             potential as well as fertile men and their partners who are female of reproductive&#xD;
             potential must agree to abstain from sexual intercourse or to use two highly effective&#xD;
             forms of contraception from the time of giving informed consent, during the study and&#xD;
             for 120 days (females and males) following the last dose of AG-221. A highly effective&#xD;
             form of contraception is defined as hormonal oral contraceptives, injectables,&#xD;
             patches, intrauterine devices.&#xD;
&#xD;
        Male patients must :&#xD;
&#xD;
        Agree the need for the use of a condom if engaged in sexual activity with a woman of&#xD;
        childbearing potential during the entire period of treatment, even if disruption of&#xD;
        treatment and during 3 months after end of treatment.&#xD;
&#xD;
        Agree to learn about the procedures for preservation of sperm before starting treatment&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        A patient meeting any of the following criteria is not eligible to participate in the&#xD;
        study:&#xD;
&#xD;
          1. Severe infection or any other uncontrolled severe condition.&#xD;
&#xD;
          2. Significant cardiac disease - New York Heart Association (NYHA) Class III or IV or&#xD;
             having suffered a myocardial infarction in the last 6 months.&#xD;
&#xD;
          3. Less than 14 days since prior treatment with growth factors (EPO, G-CSF).&#xD;
&#xD;
          4. Use of investigational agents within 30 days or any anticancer therapy within 2 weeks&#xD;
             before the study entry with the exception of hydroxyurea. The patient must have&#xD;
             recovered from all acute toxicity from any previous therapy.&#xD;
&#xD;
          5. Subject has a heart-rate corrected QT interval using Fridericia's method (QTcF) ≥ 470&#xD;
             msec or any other factor that increases the risk of QT prolongation or arrhythmic&#xD;
             events (e.g., heart failure, hypokalemia, family history of long QT interval&#xD;
             syndrome). Subjects with prolonged QTcF interval in the setting of bundle branch block&#xD;
             may participate in the study.&#xD;
&#xD;
          6. Active cancer or cancer during the year prior to trial entry other than basal cell&#xD;
             carcinoma, or carcinoma in situ of the cervix or breast.&#xD;
&#xD;
          7. Patient already enrolled in another therapeutic trial of an investigational drug.&#xD;
&#xD;
          8. Known HIV infection or active hepatitis B or C.&#xD;
&#xD;
          9. Women who are or could become pregnant or who are currently breastfeeding.&#xD;
&#xD;
         10. Any medical or psychiatric contraindication that would prevent the patient from&#xD;
             understanding and signing the informed consent form.&#xD;
&#xD;
         11. Patient eligible for allogeneic stem cell transplantation.&#xD;
&#xD;
         12. Known allergies to AG-221 or any of its excipients.&#xD;
&#xD;
         13. No affiliation to a health insurance system.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionel ADES, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatiha Chermat, Director</last_name>
    <phone>33171207059</phone>
    <email>fatiha.chermat-ext@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lamya Ait Si Selmi, MS</last_name>
    <phone>33171207055</phone>
    <email>lamya.aitsiselmi-ext@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH d'Angers/Service des Maladies du sang</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain THEPOT, MD</last_name>
      <phone>02 41 35 44 66</phone>
      <email>sylvain.thepot@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain THEPOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>centre hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin PAPOULAR, MD</last_name>
      <phone>0134232016</phone>
      <email>benjamin.papoular@ch-argenteuil.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de la Cote Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne BANOS, MD</last_name>
      <phone>0559443832</phone>
      <email>abanos@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Anne BANOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>sophie DIMICOLI-SALAZAR, MD</last_name>
      <phone>0557656511</phone>
      <email>sophie.dimicoli-salzar@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre/Service d'Hématologie Clinique</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane CHEZE, MD</last_name>
      <phone>02 31 27 23 60</phone>
      <email>cheze-s@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphane CHEZE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sébastien Maury, MD</last_name>
      <phone>01 49 81 20 57</phone>
      <email>sebastien.maury@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Park, Pr</last_name>
      <phone>0476766277</phone>
      <email>spark@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Le Mans/Service d'hématologie Oncologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamel Laribi, MD</last_name>
      <phone>02 43 43 43 61</phone>
      <email>klaribi@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Kamel Laribi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaelle Fossard, MD</last_name>
      <phone>04 78 86 22 69</phone>
      <email>gaelle.fossard@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes/Unité d'Hématologie 3</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert Vey, Pr</last_name>
      <phone>04 91 22 36 95</phone>
      <email>veyn@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert Vey, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GHR Mulhouse Sud-Alsace</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario OJEDA-URIBE, MD</last_name>
      <phone>0389647755</phone>
      <email>ojeda-uribem@ghrmsa.fr</email>
    </contact>
    <investigator>
      <last_name>Mario OJEDA-URIBE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hôtel Dieu/Service d'Hématologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Peterlin, MD</last_name>
      <phone>02 40 08 32 71</phone>
      <email>pierre.peterlin@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Peterlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet 1/Service d'Hématologie Clinique</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas cluzeau, Pr</last_name>
      <phone>04 92 03 58 44</phone>
      <email>cluzeau.t@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas Cluzeau, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>stefan wickenheuser, MD</last_name>
      <phone>0466684033</phone>
      <email>stefan.wickenhauser@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - Service d'hématologie séniors</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel ADES, MD, PHD</last_name>
      <phone>+33 1 70 20 70 22</phone>
      <email>lionel.ades@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Lionel ADES, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ollivier legrand, Pr</last_name>
      <phone>0149283429</phone>
      <email>ollivier.legrand@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel/Département d'Hématologie</name>
      <address>
        <city>Rouen</city>
        <zip>76 038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
      <phone>02 32 08 22 88</phone>
      <email>aspasia.stamatoullas@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie Lucien Neuwirth Saint priest en Jarez</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>caroline lejeune</last_name>
      <phone>04 77 91 71 60</phone>
      <email>caroline.lejeune@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Médecine Interne/IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odile BEYNE-RAUZY, Pr</last_name>
      <phone>+33(0)5 31 15 62 64</phone>
      <email>beynerauzy.odile@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Odile BEYNE-RAUZY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel GYAN, MD</last_name>
      <phone>02 47 47 37 12</phone>
      <email>emmanuel.gyan@univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

